Overall rank by patents
#46,432
Across all tracked assignees
USPTO 2015–2025 USPTO PatentsView Foreign Corporation
Entos Pharmaceuticals Inc.
USPTO PatentsView assignee record - 5 granted patents across 5 technology areas, active 2019–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: C07K (PEPTIDES).
5
Total patents granted
5
CPC technology areas
5.8
Avg claims per patent
+300%
5-year filing velocity
The verdict
Entos holds 5 US patents across 5 technology areas, rank #46,432 of 50,000 tracked assignees.
- #46,432
- of 50,000 US assignees by volume
- Top 64%
- by Innovation Score (30.9/100)
- 5.8
- avg claims per patent
- +300%
- filing velocity, last 5 yrs
Portfolio overview
Entos Pharmaceuticals Inc. has been granted 5 US utility patents between 2019 and 2025, placing Entos Pharmaceuticals Inc. at rank #46,432 across all assignees tracked by PlainPatent. This portfolio spans 5 distinct Cooperative Patent Classification (CPC) subclasses, averaging 5.8 claims per patent with primary concentration in C07K (PEPTIDES). As a Foreign Corporation, Entos Pharmaceuticals Inc. is one of the more focused assignees in the PatentsView dataset. By volume, Entos sits between Enodis Corporation (5 patents, rank #46,428) and Envirosystems Inc. (5 patents, rank #46,436) - the closest US assignees by grant volume. The composite Innovation Score of 30.9/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Between 2020 and 2025 the company received 4 grants, compared with 1 in the 2015–2019 window, a +300% shift in five-year velocity. An acceleration of this magnitude signals aggressive R&D investment and expanding technical ambition. The Foreign Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. Entos Pharmaceuticals Inc.'s 5.8 average claims per patent suggests focused, narrowly drawn claims typical of single-invention filings, while concentration in 5 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Entos Pharmaceuticals Inc. against peers pursuing similar technology classes.
Who files at Entos's volume?
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
- Enodis
ENODIS CORPORATION
5 patents
- Enscp—Chimie Pari…
ENSCP—CHIMIE PARISTECH—ECOLE NATIONALE SUPERIEURE DE CHIME DE PARIS
5 patents
- Enterin Laborator…
ENTERIN LABORATORIES, INC.
5 patents
- Entex
ENTEX Technologies Inc.
5 patents
- Entsorgafin S P A
ENTSORGAFIN S.P.A.
5 patents
- Entuity
ENTUITY LIMITED
5 patents
- Environmental Ene…
ENVIRONMENTAL ENERGY SERVICES, INC.
5 patents
- Envirosystems
ENVIROSYSTEMS INC.
5 patents
- Entos Pharmaceuti… ◀
ENTOS PHARMACEUTICALS INC.
5 patents
What this shows Entos holds 5 patents at rank #46,432, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Companies ranked near Entos
By rank, the assignees closest to #46,432 in granted patent volume.
- Enodis Corporation #46,428 · 5 patents
- Enscp—chimie Paristech—ecole Nationale Superieure DE Chime DE Paris #46,429 · 5 patents
- Enterin Laboratories, Inc. #46,430 · 5 patents
- Entex Technologies Inc. #46,431 · 5 patents
- Entsorgafin S.p.a. #46,433 · 5 patents
- Entuity Limited #46,434 · 5 patents
- Environmental Energy Services, Inc. #46,435 · 5 patents
- Envirosystems Inc. #46,436 · 5 patents
Leaders in C07K (Peptides)
Other assignees with the most granted patents in Entos's primary technology class.
- The Regents Of The University Of California 894 in class
- Regeneron Pharmaceuticals, Inc. 824 in class
- Immatics Biotechnologies Gmbh 678 in class
- Genentech, Inc. 565 in class
- The United States Of America, As Represented By The Secretary, Department Of Health And Human Services 513 in class
- The Trustees Of The University Of Pennsylvania 501 in class
- Novartis Ag 407 in class
- The Board Of Trustees Of The Leland Stanford Junior University 400 in class
Entos's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
31 Top 64% higher than 36% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Grants by year
Teal-shaded recent years (2020–present) versus the 2019–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2019 | 1 | 20.0% |
| 2022 | 2 | 40.0% |
| 2025 | 2 | 40.0% |
Which technologies does Entos Pharmaceuticals Inc. patent most?
Top 5 of 5 technology areas
Patent Moat Analysis
Portfolio Volume Light
Tech Breadth Focused
Claim Depth Simple
Velocity Accelerating
Frequently Asked Questions
How many patents does Entos Pharmaceuticals Inc. hold?
Entos Pharmaceuticals Inc. holds 5 US granted patents filed between 2019 and 2025, spanning 5 technology areas.
What is Entos Pharmaceuticals Inc.'s Innovation Score?
Entos Pharmaceuticals Inc. has an Innovation Score of 30.9 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does Entos Pharmaceuticals Inc. focus on?
Entos Pharmaceuticals Inc.'s top technology area is C07K (PEPTIDES) with 5 patents. The company has filed patents in 5 CPC subclasses total.
Is Entos Pharmaceuticals Inc.'s patent filing rate increasing or decreasing?
Entos Pharmaceuticals Inc.'s recent filing velocity is +300% compared to the prior five-year period. This indicates accelerating innovation.
What does claim depth mean for Entos Pharmaceuticals Inc.'s patents?
Entos Pharmaceuticals Inc.'s patents average 5.8 claims each. This is relatively simple claim structure, typical for focused inventions.
How is the Entos Pharmaceuticals Inc. patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.
How to use this portfolio
Entos's 5 grants land it in the top 64% by Innovation Score, but volume alone doesn't tell you where the strength sits.
- Read that count against the largest US assignees before treating it as dominance - Entos ranks #46,432 of 50,000. Top 50 holders
- Most of this portfolio concentrates in C07K - see who else leads that technology area. C07K leaders
- Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.